51
|
Scherlinger M, Pellegrin JL, Germain V, Lazaro E, Duffau P, Schaeverbeke T. [Biosimilars in France, to understand the stakes in order to use them well]. Rev Med Interne 2018; 40:5-8. [PMID: 30396704 DOI: 10.1016/j.revmed.2018.10.383] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2018] [Accepted: 10/14/2018] [Indexed: 11/19/2022]
Affiliation(s)
- M Scherlinger
- Service de rhumatologie, hôpital Pellegrin, CHU de Bordeaux, place Amélie-Raba-Léon, 33076 Bordeaux, France; Université de Bordeaux, 146, rue Léo-Saignat, 33076 Bordeaux, France; Centre de référence maladies auto-immunes et systémiques rare Est/Sud-Ouest, CHU de Bordeaux, 33076 Bordeaux, France.
| | - J-L Pellegrin
- Université de Bordeaux, 146, rue Léo-Saignat, 33076 Bordeaux, France; Service de médecine interne, hôpital Haut-Levêque, CHU de Bordeaux, avenue Magellan, 33600 Pessac, France; Centre de référence maladies auto-immunes et systémiques rare Est/Sud-Ouest, CHU de Bordeaux, 33076 Bordeaux, France
| | - V Germain
- Service de rhumatologie, hôpital Pellegrin, CHU de Bordeaux, place Amélie-Raba-Léon, 33076 Bordeaux, France; Université de Bordeaux, 146, rue Léo-Saignat, 33076 Bordeaux, France; Centre de référence maladies auto-immunes et systémiques rare Est/Sud-Ouest, CHU de Bordeaux, 33076 Bordeaux, France
| | - E Lazaro
- Université de Bordeaux, 146, rue Léo-Saignat, 33076 Bordeaux, France; Service de médecine interne, hôpital Haut-Levêque, CHU de Bordeaux, avenue Magellan, 33600 Pessac, France; Centre de référence maladies auto-immunes et systémiques rare Est/Sud-Ouest, CHU de Bordeaux, 33076 Bordeaux, France
| | - P Duffau
- Université de Bordeaux, 146, rue Léo-Saignat, 33076 Bordeaux, France; Service de médecine interne, hôpital Saint-André, CHU de Bordeaux, 1, rue Jean-Burguet, 33000 Bordeaux, France; Centre de référence maladies auto-immunes et systémiques rare Est/Sud-Ouest, CHU de Bordeaux, 33076 Bordeaux, France
| | - T Schaeverbeke
- Service de rhumatologie, hôpital Pellegrin, CHU de Bordeaux, place Amélie-Raba-Léon, 33076 Bordeaux, France; Université de Bordeaux, 146, rue Léo-Saignat, 33076 Bordeaux, France; Centre de référence maladies auto-immunes et systémiques rare Est/Sud-Ouest, CHU de Bordeaux, 33076 Bordeaux, France
| |
Collapse
|
52
|
Germain V, Scherlinger M, Barnetche T, Schaeverbeke T. Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect. Ann Rheum Dis 2018; 79:e11. [PMID: 30352888 DOI: 10.1136/annrheumdis-2018-214374] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2018] [Revised: 10/01/2018] [Accepted: 10/06/2018] [Indexed: 11/04/2022]
Affiliation(s)
- Vincent Germain
- Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux, Service de Rhumatologie, Bordeaux, France.,Department of Rheumatology, Université de Bordeaux, Bordeaux, France
| | - Marc Scherlinger
- Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux, Service de Rhumatologie, Bordeaux, France.,Department of Rheumatology, Université de Bordeaux, Bordeaux, France.,Department of Rheumatology, CNRS-UMR 5164 Immuno ConcEpT, Bordeaux, France
| | - Thomas Barnetche
- Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux, Service de Rhumatologie, Bordeaux, France
| | - Thierry Schaeverbeke
- Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux, Service de Rhumatologie, Bordeaux, France .,Department of Rheumatology, Université de Bordeaux, Bordeaux, France
| | | |
Collapse
|
53
|
Scavone C, Sessa M, Clementi E, Corrao G, Leone R, Mugelli A, Rossi F, Spina E, Capuano A. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study. BioDrugs 2018; 32:607-617. [PMID: 30341487 PMCID: PMC6290713 DOI: 10.1007/s40259-018-0313-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND In recent years, several biosimilar drugs, including those of infliximab, have obtained marketing authorization from the European Medicines Agency (EMA). Given the peculiarity of the safety profile of biological medical products (originator and biosimilars), the evaluation of their tolerability represents an important component of pre-marketing and post-marketing clinical development. For example, infliximab products may cause adverse drug reactions (ADRs) including acute infusion reactions, delayed hypersensitivity reactions, and loss of efficacy, as a direct consequence of immunogenicity. Therefore, specific contraindications, special warnings and precautions have been introduced in the infliximab Summary of Product Characteristics (SPC). OBJECTIVE The aim was to assess the magnitude of preventable ADRs in individual case safety reports (ICSRs) having infliximab as a suspected drug across Italy (using the spontaneous reporting systems), and the probability of reporting infections, infusion reactions, lack of efficacy, and hypersensitivity for originator and biosimilars of infliximab. METHODS We analyzed ADRs reported across the 2015-2017 period in the databases of five Italian regions: Campania, Lombardy, Sicily, Tuscany, and Veneto. Preventability of ADRs was assessed using the P-method. To compare the probability of reporting infections, infusion reactions, lack of efficacy, and hypersensitivity as ADRs as opposed to other types of ADRs between originator and biosimilars of infliximab, we used the reporting odds ratio (ROR). For descriptive purposes, the number of ICSRs involving infliximab, the number of infliximab vials distributed in the aforementioned Italian regions and the relative reporting rate stratified by semester were reported. RESULTS From October 2015 to October 2017, 459 ICSRs reported infliximab as a suspected drug (222 ICSRs related to infliximab originator and 237 to infliximab biosimilars). In the same period, 81,906 vials of infliximab were distributed, resulting in a reporting rate of six ICSRs/1000 vials. Overall, 34 cases (7.41%) were categorized as preventable. The most frequently detected critical criteria were "documented hypersensitivity to administered drug or drug class," "inappropriate prescription for patient's underlying medical condition" and "incorrect dose." Biosimilars had, in adjusted analyses, an increased probability of being reported as suspected in ICSRs reporting infusion reactions (ROR 4.09; 95% confidence interval [CI] 1.26-13.32) when compared to Remicade®. On the contrary, they had a decreased probability of being reported as suspected in ICSRs reporting infections or lack of efficacy (ROR 0.33; 95% CI 0.12-0.89; ROR 0.35; 95% CI 0.20-0.61). CONCLUSION Our study demonstrates that, along with a rapid increase in the utilization of infliximab biosimilars across Italy, there was also an increase in reporting ADRs induced by infliximab biosimilars. Of the reported ADRs, 7.4% were considered preventable. In adjusted analyses, infliximab biosimilars were shown to have an increased probability of being reported as suspected drugs in infusion reactions and a decreased probability of being reported as suspected drugs in cases of lack of efficacy or infection. Considering the potential advantages offered by the utilization of biosimilars in clinical practice, we believe that the use of biosimilars, including those of infliximab, should be supported. In order to achieve this aim, increased knowledge on safety and efficacy of biosimilar drugs should be obtained from real world clinical practice.
Collapse
Affiliation(s)
- Cristina Scavone
- Campania Pharmacovigilance and Pharmacoepidemiology Regional Centre, Section of Pharmacology "L. Donatelli", Department of Experimental Medicine, University of Campania "L. Vanvitelli", Naples, Italy.
| | - Maurizio Sessa
- Campania Pharmacovigilance and Pharmacoepidemiology Regional Centre, Section of Pharmacology "L. Donatelli", Department of Experimental Medicine, University of Campania "L. Vanvitelli", Naples, Italy.,Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark
| | - Emilio Clementi
- Department of Biomedical and Clinical Sciences, L. Sacco University Hospital, Università di Milano, Milan, Italy.,Unit of Clinical Pharmacology, Scientific Institute, IRCCS E. Medea, Lecco, Italy
| | - Giovanni Corrao
- Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy.,National Centre for Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, Milan, Italy
| | - Roberto Leone
- Pharmacology Unit, Department of Diagnostics and Public Health, University of Verona, Verona, Italy
| | - Alessandro Mugelli
- Department of Neurosciences, Drug Research and Child's Health, University of Florence, Florence, Italy
| | - Francesco Rossi
- Campania Pharmacovigilance and Pharmacoepidemiology Regional Centre, Section of Pharmacology "L. Donatelli", Department of Experimental Medicine, University of Campania "L. Vanvitelli", Naples, Italy
| | - Edoardo Spina
- Unit of Clinical Pharmacology, AOU Policlinico "G. Martino", Messina, Sicily, Italy.,Department of Clinical and Experimental Medicine, University of Messina, Messina, Sicily, Italy
| | - Annalisa Capuano
- Campania Pharmacovigilance and Pharmacoepidemiology Regional Centre, Section of Pharmacology "L. Donatelli", Department of Experimental Medicine, University of Campania "L. Vanvitelli", Naples, Italy
| |
Collapse
|
54
|
Kristensen LE, Alten R, Puig L, Philipp S, Kvien TK, Mangues MA, van den Hoogen F, Pavelka K, Vulto AG. Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent. BioDrugs 2018; 32:397-404. [PMID: 30269270 PMCID: PMC6182448 DOI: 10.1007/s40259-018-0306-1] [Citation(s) in RCA: 71] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The nocebo effect is defined as the incitement or the worsening of symptoms induced by any negative attitude from non-pharmacological therapeutic intervention, sham, or active therapies. When a patient anticipates a negative effect associated with an intervention, medication or change in medication, they may then experience either an increase in this effect or experience it de novo. Although less is known about the nocebo effect compared with the placebo effect, widespread interest in the nocebo effect observed with statin therapy and a literature review highlighting the nocebo effect across at least ten different disease areas strongly suggests this is a common phenomenon. This effect has also recently been shown to play a role when introducing a medication or changing an established medication, for example, when switching patients from a reference biologic to a biosimilar. Given the important role biosimilars play in providing cost-effective alternatives to reference biologics, increasing physician treatment options and patient access to effective biologic treatment, it is important that we understand this phenomenon and aim to reduce this effect when possible. In this paper, we propose three key strategies to help mitigate the nocebo effect in clinical practice when switching patients from reference biologic to biosimilar: positive framing, increasing patient and healthcare professionals' understanding of biosimilars and utilising a managed switching programme.
Collapse
Affiliation(s)
- Lars Erik Kristensen
- Parker Institute, University of Copenhagen, Bispebjerg og Frederiksberg, Frederiksberg, Denmark
- Department of Internal Medicine, Rheumatology, Lund University, Lund, Sweden
| | - Rieke Alten
- Department of Internal Medicine, Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany
| | - Luis Puig
- Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
| | - Sandra Philipp
- Department of Dermatology, Venereology and Allergy, Charité Universitätsmedizin, Berlin, Germany
| | - Tore K Kvien
- Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
| | | | - Frank van den Hoogen
- Department of Rheumatology, Sint Maartenskliniek and Radboud University Medical Centre, Nijmegen, The Netherlands
| | | | - Arnold G Vulto
- Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
| |
Collapse
|
55
|
Yoo DH, Choe JY, Shim SC, Suh CH. Switching to biosimilars in the treatment of rheumatic diseases. Expert Rev Clin Immunol 2018; 14:557-571. [DOI: 10.1080/1744666x.2018.1490178] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Dae Hyun Yoo
- Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
| | - Jung-Yoon Choe
- Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea
| | - Seung Cheol Shim
- Division of Rheumatology, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Republic of Korea
| | - Chang-Hee Suh
- Department of Rheumatology, Ajou University School of Medicine, Suwon, Republic of Korea
| |
Collapse
|
56
|
Scherlinger M, Schaeverbeke T. Additional response to the correspondence: ‘Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?’ by Cantini and Bennuci. Ann Rheum Dis 2018. [DOI: 10.1136/annrheumdis-2018-213342] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
57
|
Scherlinger M, Schaeverbeke T. Response to: ‘Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?’ by Cantini and Benucci. Ann Rheum Dis 2018; 78:e24. [DOI: 10.1136/annrheumdis-2018-213021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2018] [Accepted: 01/17/2018] [Indexed: 11/04/2022]
|